Texas Gov. Greg Abbott on June 11 signed a bill creating a consortium of universities, hospitals and pharmaceutical firms to conduct clinical trials on ibogaine, in hopes of receiving US Food & Drug Administration approval. The press release on the signing hails ibogaine as an "emerging treatment for neurological and mental health conditions." Lawmakers approved $50 million to support the effort, making Texas the global leader in psychedelic research investment. (Texas Tribune)


Next week, the Multidisciplinary Association for Psychedelic Studies (MAPS) will bring a host of psychedelic scientists and visionary artists together in San Jose, California for the largest conference of its kind in the U.S. in 17 years.





Recent comments
2 weeks 3 days ago
3 weeks 1 day ago
13 weeks 1 day ago
17 weeks 2 days ago
18 weeks 2 days ago
18 weeks 2 days ago
39 weeks 3 days ago
43 weeks 4 days ago
45 weeks 1 day ago
45 weeks 2 days ago